Data gathered: June 22
AI Stock Analysis - Gilead Sciences (GILD)
Analysis generated March 11, 2025. Powered by Chat GPT.
Gilead Sciences, Inc. is an American biopharmaceutical company that focuses on the research, development, and commercialization of treatments for life-threatening diseases. Founded in 1987 and headquartered in Foster City, California, Gilead has grown into a prominent player in the biotechnology industry. The company’s portfolio includes treatments for HIV/AIDS, liver diseases, cancer, and inflammatory diseases. Gilead is known for its innovative approach to drug development, making it a key player in the healthcare sector.
Stock Alerts - Gilead Sciences (GILD)
 |
Gilead Sciences | June 19 Marjorie Taylor Greene (member of U.S. congress) is buying shares |
|
Gilead Sciences | June 18 Insider Alert: Mercier Johanna is selling shares |
|
Gilead Sciences | June 16 AI Score is up by 32.9% in the last couple of days. |
|
Gilead Sciences | June 15 AI Score is up by 32.1% in the last couple of days. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Gilead Sciences
About Gilead Sciences
Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.
| Price | $108.50 |
| Target Price | Sign up |
| Volume | 21,540,000 |
| Market Cap | $135B |
| Year Range | $83.15 - $115.75 |
| Dividend Yield | 2.93% |
| PE Ratio | 22.79 |
| Analyst Rating | 62% buy |
| Industry | Biotechnology |
In the news
 |
Gilead Sciences, Inc. (NASDAQ:GILD) Holdings Boosted by Blue Trust Inc.June 22 - ETF Daily News |
|
Robertson Stephens Wealth Management LLC Has $383,000 Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)June 20 - ETF Daily News |
 |
Gilead Sciences (NasdaqGS:GILD) Gains FDA Approval For Yeztugo As PrEP HIV OptionJune 19 - Yahoo |
|
Sowell Financial Services LLC Buys Shares of 8,142 Gilead Sciences, Inc. (NASDAQ:GILD)June 19 - ETF Daily News |
|
Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-TermJune 18 - Yahoo |
|
Gilead Sciences’ Yeztugo receives approval from US FDA for HIVJune 18 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 6.67B | 961M | 5.71B | 1.32B | 1.91B | 1.810 |
| Q4 '24 | 7.57B | 1.58B | 5.99B | 1.78B | 3.11B | 1.900 |
| Q3 '24 | 7.55B | 1.57B | 5.97B | 1.25B | 1.88B | 2.020 |
| Q2 '24 | 6.95B | 1.54B | 5.41B | 1.61B | 2.98B | 2.010 |
| Q1 '24 | 6.69B | 1.55B | 5.13B | -4.17B | -3.54B | -1.320 |
Insider Transactions View All
| Mercier Johanna filed to sell 120,168 shares at $110.2. June 17 '25 |
| Dickinson Andrew D filed to sell 165,110 shares at $110.2. June 17 '25 |
| O'Day Daniel Patrick filed to sell 620,268 shares at $111. June 2 '25 |
| O'Day Daniel Patrick filed to sell 623,852 shares at $110.1. June 2 '25 |
| Mercier Johanna filed to sell 121,152 shares at $107.5. May 23 '25 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Marjorie Taylor Greene |
Jun 19, 25 | Buy | $1K - $15K |
| Josh Gottheimer |
Jun 12, 25 | Sell | $1K - $15K |
| Marjorie Taylor Greene |
May 7, 25 | Buy | $1K - $15K |
Read more about Gilead Sciences (GILD) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Gilead Sciences?
The Market Cap of Gilead Sciences is $135B.
What is Gilead Sciences' PE Ratio?
As of today, Gilead Sciences' PE (Price to Earnings) ratio is 22.79.
What is the current stock price of Gilead Sciences?
Currently, the price of one share of Gilead Sciences stock is $108.50.
How can I analyze the GILD stock price chart for investment decisions?
The GILD stock price chart above provides a comprehensive visual representation of Gilead Sciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Gilead Sciences shares. Our platform offers an up-to-date GILD stock price chart, along with technical data analysis and alternative data insights.
Does GILD offer dividends to its shareholders?
Yes, Gilead Sciences (GILD) offers dividends to its shareholders, with a dividend yield of 2.93%. This dividend yield represents Gilead Sciences' commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Gilead Sciences in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Gilead Sciences?
Some of the similar stocks of Gilead Sciences are Amgen, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Anavex Life Sciences, and BridgeBio Pharma.
.